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ABSTRACT
Anti N-methyl-D-aspartate (NMDA) re-ceptor en-cephalitis is an immune medi-ated disorder and it is a dis-order of the limbic system that largely 
af-fects female children. Anti-NMDA recep-tor encephalitis was actually described as a paraneoplastic syndrome as it is associated with ovarian 
teratomas con-taining neural tissue with an-tibodies cross reacting to the NMDA recep-tors. Here we discuss a case of NMDA re-ceptor en-cephalitis.
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INTRODUCTION
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a 
disorder in which the antibodies are against the NR1 subunit of the 
receptor which is usually binds to glycine [1]. Anti-NMDA receptor 
encephalitis was actually described as a paraneoplastic syndrome [2] 
as it is associated with ovarian teratomas containing neural tissue 
with antibodies cross reacting to the NMDA receptors [3] Clinical 
manifestations include (1) Prodromal phase charecterized by headache, 
fever and nausea (nonspecific symptoms), (2) psychotic phase with 
grandiose delusions, amnesia, cognitive decline, emotional disturbances 
and altered behavior, (3) unresponsive phase with catalepsy-like 
symptoms (rigid body, rigid limbs, slowing down of bodily functions 
like breathing, loss of muscle control) and athetoid dystonic posturing, 
(4) hyperkinetic phase with oro-facial limb dyskinesias, and (5) gradual 
or complete recovery during the recovery phase.
CASE REPORT
A female child, aged 17 years, came to our hospital with generalized 
tonic–clonic seizures. Earlier she was admitted in a government hospital 
for seizure, headache, and fever. She was treated with Mepresso (methyl 
prednisolone) 1 g OD, Esticef (ceftriaxone + salbactum) 1.5 g BD, 
Encorate (sodium valproate) 500 mg TID, Rabicon (rabeprazole) 20 mg 
OD and her conditions were improved. But then irrelevant talking and 
aggressiveness along with visual hallucinations occurred. So admitted 
in local hospital and was started with antipsychotics, but no significant 
improvement seen. Magnetic resonance imaging (MRI) was normal. 
Abdominal and pelvic ultrasonography done and showed mature 
ovarian teratoma and hence operated with left ovarian salpingo-
oophorectomy. Again she had a fever, visual hallucinations, and seizure 
occurred, so came to our hospital. She had given tablet encorate 
(sodium valproate) 500 mg 1-0-1, injection Levipil (levetiracetam) 
500 mg 1-1-1, tablet quetiapine 25 mg 1-0-2 and injection ceftriaxone 
1 g 1-0-1 (empirical therapy) were given. Her liver enzymes were raised 
(serum glutamic oxaloacetic transaminase [SGOT] - 1.97 µkat/L and 
serum glutamic pyruvic transaminase [SGPT] - 2.55 µkat/L).
So on next day, she was given tablet Udiliv (ursodeoxycholic 
acid) 300 mg 1-0-1 was given. Neuroimmunology results showed positive 
for cerebrospinal fluid NMDA type of glutamate receptor antibody and 
serum NMDA antibody but negative for leucine-rich glioma inactivated 
1 antibodies, voltage-gated potassium channel antibodies and CASPR2 
antibodies by immunofluorescence on transfected cells. She was diagnosed 
with anti NMDAR encephalitis in March 2016 and was given first cycle 
intravenous (IV) immunoglobulin (Ig) (60 g) and injection solu-medrol 
(methylprednisolone) 1 g. Tablet encorate was stopped. Then, tablet 
clonazepam 0.25 mg 1-1-1, tablet bromocriptine 5 mg TID, tablet pacitane 
(trihexyphenidyl) 2 mg TID, mucomix nebulization (acetyl cysteine) 
BD, syrup ambrolite 5 ml TID were given. Her temperature increased 
(103°F), both respiratory rate (12 breaths/min) and blood pressure (BP) 
reduced (103/66 mmHg). Now ecchymosis was present on both radial 
due to the administration of prednisolone. For that supportive measures 
were taken. Urine culture report showed the presence of Escherichia 
coli (700 cfu/ml) and given injection cefoperazone + sulbactam 2 g 1-0-
1. Again her liver enzymes raised (SGOT - 2.33 µkat/L and SGPT - 3.03 
µkat/L) and she had gaze and catatonic features. Since she was not 
responding to first-line agents (IV Ig and prednisolone) started on 
second-line agent rituximab (500 mg IV). Tablet clonazepam was stopped 
because she was resistant to it. Since she is allergic to haloperidol, tablet 
phenergan 25 mg 1-1-1 was given. Then her temperature reduced (98°F), 
BP get normal (127/90 mmHg), eye contact occurred and was trying to 
speak. And for deep venous thrombosis prophylaxis, heparin was given. 
Now her conditions were improved. Her liver enzymes become 0.43 
µkat/L (SGOT) and 0.57 µkat/L (SGPT). The patient was given four doses 
of rituximab and two doses of injection cyclophosphamide according to 
infusion protocol with strict monitoring infection parameters. Cataleptic 
symptoms reduced. She respond to the commands and tried to woke up. 
Then physical medicine and rehabilitation (PMR) consultation was done 
and their advice followed for rehabilitation. Plan is to discharge the patient 
and admit under PMR for active rehabilitation.
DISCUSSION
The patient brought to the hospital, with complaints of fever, headache, 
visual hallucinations, irrelevant speech, and abnormal behavior. 
In her progression phase, she had experienced insomnia, seizures, 
dyskinesias tremulousness of lower limb and alternating periods of 
agitation and autonomic instability characterized by tachycardia, 
bradycardia, central hypoventilation, hypotension, and hyperthermia 
[4]. MRI brain showed multifocal right parietal and occipital cortical 
T2 fluid attenuation inversion recovery hyperintensity which shows 
mild hyperintense signal on diffusion-weighted imaging and apparent 
diffusion coefficient sequence. Since the patient had mature ovarian 
teratoma, she underwent left ovarian salpingo-oophorectomy and 
started IV Igs (60 g) and methylprednisolone (IV Ig) as first-line therapy. 
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Since the patient did not respond to first-line treatment, she was started 
on second-line agent rituximab (500 mg, IV) and the patient was found 
to be gradually improving.
CONCLUSION
There is strong relationship between ovarian teratoma and NMDAR 
encephalitis. Hence, early diagnosis and the proper selection of 
medicine are essential to treat the patient’s condition and diseases.
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